ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ACADIA Pharmaceuticals Inc. (ACAD) Healthcare & Pipeline Overview

ACADIA Pharmaceuticals Inc. is a leading biopharmaceutical firm focused on innovative treatments for central nervous system disorders, with a strong emphasis on addressing unmet medical needs through its advanced drug pipeline and established market presence.

What Is the Investment Thesis for ACAD?

ACADIA Pharmaceuticals Inc. is strategically positioned for growth due to its focus on central nervous system disorders, a sector with significant unmet medical needs. The company's flagship product, NUPLAZID, has demonstrated strong market performance, contributing to a profit margin of 34.3% and a gross margin of 91.5%. The ongoing phase 3 trials for pimavanserin in Alzheimer's disease psychosis and schizophrenia present substantial growth catalysts, potentially expanding the market reach and revenue streams. Furthermore, the development of Trofinetide for Rett syndrome and ACP-044 for pain management diversifies ACADIA's portfolio, enhancing its competitive advantage. With a market capitalization of $4.75B and a P/E ratio of 9.54, ACADIA's valuation reflects its growth potential in a rapidly evolving biotechnology landscape. However, investors may want to evaluate the regulatory risks associated with drug approvals and the competitive pressures from peers in the CNS space.

Based on FMP financials and quantitative analysis

ACAD Key Highlights

Market Cap of $4.75B reflects strong investor interest and growth potential.

• P/E ratio of 9.54 indicates attractive valuation relative to industry peers.
• Profit margin of 34.3% demonstrates effective cost management and operational efficiency.
• Gross margin of 91.5% highlights the high profitability of ACADIA's product offerings.
• Beta of 0.81 suggests lower volatility compared to the broader market.

Who Are ACAD's Competitors?

ACAD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ACAD's Key Strengths?

Strong pipeline with multiple candidates in advanced clinical stages.

• High gross margin of 91.5% indicating efficient operations.
• Established market presence with NUPLAZID as a leading treatment.
• Experienced management team with a focus on CNS disorders.

What Are ACAD's Weaknesses?

Dependence on a single product for a significant portion of revenue.

• Limited product diversification compared to larger competitors.
• Ongoing regulatory risks associated with drug approvals.
• Potential challenges in clinical trial outcomes impacting future growth.

What Could Drive ACAD Stock Higher?

Phase 3 trial results for pimavanserin in Alzheimer's disease psychosis expected in Q4 2026.

• Continued sales growth of NUPLAZID contributing to revenue stability.
• Phase 2 trial results for ACP-044 anticipated in mid-2026.
• Development of Trofinetide for Rett syndrome progressing through phase 3 trials.
• Potential partnerships for international market expansion expected in late 2026.

What Are the Key Risks for ACAD?

Regulatory approval risks for ongoing clinical trials could impact product timelines.

• Competitive pressures from other biotechnology firms developing similar therapies.
• Market acceptance of new products may be slower than anticipated.
• Dependence on NUPLAZID for revenue exposes the company to financial risks.

What Are the Growth Opportunities for ACAD?

• Successful results could lead to FDA approval, expanding ACADIA's market presence and revenue potential.
• Growth opportunity 2: The development of Trofinetide for Rett syndrome, currently in phase 3 trials, targets a rare genetic disorder with limited treatment options. The market for Rett syndrome therapies is projected to grow, and ACADIA's innovative approach could position it as a leader in this niche.
• Growth opportunity 3: ACP-044, a novel non-opioid analgesic in phase 2 development, addresses the growing demand for pain management solutions amidst the opioid crisis. The global analgesics market is expected to surpass $50 billion by 2027, providing ACADIA with a substantial opportunity to capture market share.
• Growth opportunity 4: The potential approval of ACP-319, aimed at treating schizophrenia and cognition in Alzheimer's, could diversify ACADIA's portfolio further. As the schizophrenia market is projected to grow to $12 billion by 2026, this product could significantly enhance revenue streams.
• Growth opportunity 5: Expansion into international markets offers additional growth potential for ACADIA. With increasing global demand for innovative CNS therapies, establishing a presence in Europe and Asia could drive revenue growth and enhance brand recognition.

What Opportunities Does ACAD Have?

• Expansion of product offerings through successful pipeline developments.
• Potential for international market entry to increase revenue streams.
• Growing demand for innovative CNS therapies amidst rising patient populations.
• Strategic partnerships could enhance research capabilities and market reach.

What Threats Does ACAD Face?

• Intense competition from other biotechnology firms targeting CNS disorders.
• Regulatory hurdles that could delay product approvals.
• Market volatility impacting funding and investment in biotech.
• Potential for adverse clinical trial results affecting stock performance.

What Are ACAD's Competitive Advantages?

• Strong intellectual property portfolio protecting key drug formulations.
• Established reputation and trust within the healthcare community.
• Unique focus on CNS disorders with limited competition in niche markets.
• Proven track record of successful drug development and regulatory approvals.
• Robust clinical trial infrastructure supporting ongoing research initiatives.

What Does ACAD Do?

Founded in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California, and is dedicated to developing and commercializing small molecule drugs that target unmet medical needs in central nervous system (CNS) disorders. The company gained prominence with its flagship product, NUPLAZID (pimavanserin), which is the first and only FDA-approved treatment specifically for hallucinations and delusions associated with Parkinson's disease psychosis. This groundbreaking approval marked a significant milestone for ACADIA, establishing its reputation in the biopharmaceutical sector. The company has since expanded its pipeline, which includes several promising candidates in various stages of development. Currently, pimavanserin is under phase 3 development for the treatment of Alzheimer's disease psychosis and negative symptoms of schizophrenia, while Trofinetide, a novel synthetic analog, is also in phase 3 for Rett syndrome. Additionally, ACADIA is advancing ACP-044, a first-in-class non-opioid analgesic in phase 2 for acute and chronic pain, and ACP-319, a positive allosteric modulator of the muscarinic receptor in phase 1 for schizophrenia and cognition in Alzheimer's. With a workforce of 653 employees, ACADIA is positioned as a key player in the biotechnology industry, leveraging its innovative research and development capabilities to address critical healthcare challenges.

What Products and Services Does ACAD Offer?

• Develops and commercializes small molecule drugs for CNS disorders.
• Offers NUPLAZID, the first FDA-approved treatment for Parkinson's disease psychosis.
• Has a robust pipeline targeting Alzheimer's disease, Rett syndrome, and schizophrenia.
• Focuses on addressing unmet medical needs in the biopharmaceutical sector.
• Conducts clinical trials to evaluate the safety and efficacy of new therapies.
• Engages in strategic partnerships to enhance research and development capabilities.

How Does ACAD Make Money?

• Generates revenue primarily through the sale of NUPLAZID to healthcare providers and institutions.
• Pursues strategic collaborations and partnerships to co-develop new therapies.
• Invests in research and development to innovate and expand its product pipeline.
• Utilizes a direct sales force to promote its products to healthcare professionals.
• Explores licensing agreements for international distribution of its therapies.

What Industry Does ACAD Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the area of central nervous system disorders. With an increasing prevalence of neurological conditions, the market for CNS therapeutics is projected to grow substantially, driven by advancements in drug development and an aging population. ACADIA Pharmaceuticals Inc. occupies a strategic position within this landscape, leveraging its expertise in small molecule drugs to address critical healthcare needs. The competitive landscape includes notable peers such as Praxis Precision Medicines, Inc. (PRAX) and Immunovant, Inc. (IMVT), which are also focused on CNS disorders, intensifying the race for market share in this lucrative sector.

Who Are ACAD's Key Customers?

• Healthcare providers including hospitals and clinics that treat CNS disorders.
• Patients suffering from Parkinson's disease psychosis and other CNS conditions.
• Pharmaceutical distributors and wholesalers that facilitate product distribution.
• Research institutions involved in clinical trials and drug development.
• Regulatory bodies that oversee drug approvals and market access.

ACADIA Pharmaceuticals Inc. (ACAD) Valuation Context

Valued at $4.75B, ACAD is classified as a mid-cap stock. Analyst price targets span from $14.50 to $49.00, with a consensus of $33.83. At the current price of $27.74, that implies approximately 22% upside potential. Relative to its peer group, ACAD's quantitative score of 80/100 is roughly in line with the peer average of 70/100.

ACAD Revenue & Earnings Trend

In Jun 2026, ACAD generated $308.0M in top-line revenue, marking a sequential increase of 14.9%. The company recorded net income of $31.5M, with diluted EPS of $0.18. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ACAD averaged $0.56 in diluted EPS.

Company Profile

ACADIA Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Catherine E. Owen Adams. ACAD has traded publicly since 2004.

Return on equity for ACADIA Pharmaceuticals Inc. stands at 35.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 23.4%, showing how much profit it generates from its asset base. ACAD trades at a trailing price-to-earnings ratio of 9.54, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.5%, the inverse of the P/E and a quick read on earnings relative to price.

ACADIA Pharmaceuticals Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.53 places it in the safe zone, indicating low near-term bankruptcy risk.

ACADIA Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 225.2% above estimates on average.

Wall Street analysts project ACADIA Pharmaceuticals Inc. revenue of about $1.27B for fiscal 2026, with EPS near $0.61. The estimate reflects 15 contributing analysts.

Over the past six months, ACADIA Pharmaceuticals Inc. insiders filed 75 SEC Form 4 transactions — 40 sales and 35 purchases. On net that is roughly 131K shares acquired (about $545K) — insiders putting money in tends to read as conviction.

ACAD Financials

ACAD Latest News

ACAD Analyst Consensus

ACAD MoonshotScore

ACADIA Pharmaceuticals Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources